CFTR and cystic fibrosis: Here, we report an approach for individualized treatment for two patients with CF, homozygous for the G85E and N1303K mutation and for whom CFTR modulator therapy is not available in Europe, as both conditions are not approved for ETI by the European Medicines Agency (EMA) (although G85E has been approved by the FDA).